^
Association details:
| Biomarker: | WWTR1 fusion |
|---|---|
| Cancer: | Solid Tumor |
| Drug: | IAG933 (TEAD inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
LB319 / 10 - IAG933, a selective and orally efficacious YAP1/WWTR1(TAZ)-panTEAD protein-protein interaction inhibitor with pre-clinical activity in monotherapy and combinations
Published date:
03/15/2023
Excerpt:
In line with the current clinical strategy for IAG933, robust anti-tumor efficacy in cancer models bearing NF2 loss of function or expressing TAZ-fusions was observed.
